Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.32 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.32 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.32 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.32 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL315176 | 1.00 | AKT1 (0.37) | AKT1HSD17B10ALDH1A1ESR1OPRD1 | |
| SCHEMBL315177 | 1.00 | AKT1 (0.37) | AKT1HSD17B10ALDH1A1ESR1OPRD1 | |
| SCHEMBL313981 | 0.93 | OPRD1 (0.37) | AKT1HSD17B10ALDH1A1OPRD1ESR2 | |
| SCHEMBL313982 | 0.93 | OPRD1 (0.37) | AKT1HSD17B10ALDH1A1OPRD1ESR2 | |
| SCHEMBL313983 | 0.93 | OPRD1 (0.37) | AKT1HSD17B10ALDH1A1OPRD1ESR2 | |
| SCHEMBL1810101 | 0.88 | AKT1 (0.46) | AKT1HSD17B10 | |
| SCHEMBL1810105 | 0.88 | AKT1 (0.46) | AKT1HSD17B10 | |
| SCHEMBL1810103 | 0.88 | AKT1 (0.46) | AKT1HSD17B10 | |
| SCHEMBL314496 | 0.84 | CDC7 (0.36) | AKT1HSD17B10ALDH1A1ESR2HPGD | |
| SCHEMBL10098578 | 0.82 | AKT1 (0.42) | AKT1OPRD1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093240-B2 | Triazole derivatives | MERCK PATENT GMBH (DE) | 2012-01-10 | — | — | US | claimed |
| EP-2322527-A1 | Triazole derivatives | Merck Patent GmbH (DE) | 2011-05-18 | — | — | EP | claimed |
| US-20080306042-A1 | Triazole Derivatives | MERCK PATENT GMBH (DE) | 2008-12-11 | — | — | US | claimed |
| US-8093240-B2 | Triazole derivatives | MERCK PATENT GMBH (DE) | 2012-01-10 | — | — | US | disclosed |
| EP-2322527-A1 | Triazole derivatives | Merck Patent GmbH (DE) | 2011-05-18 | — | — | EP | disclosed |
| US-20080306042-A1 | Triazole Derivatives | MERCK PATENT GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306042-A1 | Triazole Derivatives | TGFBR1, TGFBR2, SMAD3 | AKT1 457/4885HSD17B10 2718/4885ALDH1A1 2295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.